Navigation Links
NKTR-102 Demonstrates Synergistic Anti-Tumor Activity in Combination with Pegylated Liposomal Doxorubicin in Platinum-Resistant Ovarian Cancer
Date:11/15/2011

SAN FRANCISCO, Nov. 15, 2011 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today presented positive preclinical data for NKTR-102, a next-generation topoisomerase I inhibitor, at the 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer being held in San Francisco, California.  The preclinical data demonstrates that NKTR-102 administered in combination with pegylated liposomal doxorubicin (PLD) in vivo has strong synergistic anti-cancer properties exhibiting a 100% complete response rate with no tumor re-growth in over 90% of animals.  In addition, the study showed that there was no additive toxicity when combining NKTR-102 with PLD in a preclinical model of ovarian cancer.

"Results from these nonclinical studies of NKTR-102 combined with PLD and as a single agent are highly compelling," said Robert Medve, M.D., Chief Medical Officer of Nektar Therapeutics. "In the models of platinum-resistant ovarian cancer, NKTR-102 showed synergistic anti-tumor activity with PLD.  These preclinical data support the future exploration of NKTR-102 in combination with PLD in platinum-resistant ovarian cancer."  

The data presented at the 2011 AACR-NCI-EORTC meeting show that in an in vivo model of platinum-resistant human ovarian cancer, a single-dose of single-agent NKTR-102 resulted in a 100 percent complete response rate and a delay in tumor growth of up to 38 days at the highest dose.  In the same model, multiple doses of single-agent PLD achieved only one partial response and a delay in tumor growth of up to only 24 days at its highest dose.  NKTR-102 administered in combination with PLD showed synergistic anti-tumor activity with a 100 percent complete response rate and no tumor re-growth for 93% of the animals within a 69-day observation period.  

NKTR-102 and PLD Nonclinical DataThese data were pres
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. First Patient Dosed in Phase 2 Clinical Trial of NKTR-102 in Ovarian Cancer
2. Significant Anti-Tumor Activity and Extended Half-Life of NKTR-102 (PEG-irinotecan) Highlighted in Phase 1 Data Presented at EORTC-NCI-AACR Symposium
3. Boston Scientific Platinum Chromium ION™ Stent Demonstrates Positive Outcomes in PERSEUS Clinical Program
4. Taksta™ (fusidic acid) Demonstrates Activity Against MRSA Isolated From Cystic Fibrosis Patients
5. SomaGenics sshRNA Technology Demonstrates Efficacy of RNAi Against Hepatitis C Virus
6. New Study Reports CancerTYPE ID Expands Tumor Type Coverage and Demonstrates Clinical Utility
7. Inovio Pharmaceuticals Prostate Cancer DNA Vaccine Demonstrates Strong T Cell Responses in Monkeys; Company on Track for Phase I Clinical Trial
8. Actinobac Biomed, Inc. Demonstrates In Vivo Efficacy for Psoriasis Treatment
9. Prototype demonstrates success of advanced new energy technology
10. EntreMeds ENMD-2076 Demonstrates Clinical Activity in Recurrent, Platinum-Resistant Ovarian Cancer Patients
11. Juventas Therapeutics Demonstrates JVS-100 Delivery to Patients with Heart Failure is Safe and Provides Clinical Benefit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... 2014 Research and Markets  has announced ... Analyzer, and Gas Chromatograph Market by Type , Technology, ... Trends & Forecast to 2013 - 2020" report ... is a process analytical instrument that provides chemical composition ... the way by which companies carry out their production ...
(Date:9/29/2014)... , Sept. 29, 2014 Burnham Securities ... Channel Group ("TCG"), a leader in healthcare venture ... formed an alliance to expand the range of ... With the alliance, Burnham Securities will be supported ... clinical medicine and management in healthcare industry to ...
(Date:9/29/2014)... , September 29, 2014 Atox ... severe infections, today announced that the Biomedical Advanced Research ... Bio with a contract valued up to $24 million ... treat Necrotizing Soft Tissue Infections (NSTI) and potentially infections ... in sepsis. BARDA awarded the contract to ...
(Date:9/29/2014)... Westbridge Agricultural Products announced today the ... effective new tool for organic growers. SUPPRESS™ Herbicide ... herbicide for post-emergent, non-selective weed control for use ... formulation is an emulsifiable concentrate that has been ... for use in organic food production. , In ...
Breaking Biology Technology:Global Process Liquid Analyzer, Gas Analyzer, and Gas Chromatograph (PH/ORP, Chlorine, Oxygen, Carbon dioxide) Market - Trends & Forecast to 2020 2Global Process Liquid Analyzer, Gas Analyzer, and Gas Chromatograph (PH/ORP, Chlorine, Oxygen, Carbon dioxide) Market - Trends & Forecast to 2020 3Global Process Liquid Analyzer, Gas Analyzer, and Gas Chromatograph (PH/ORP, Chlorine, Oxygen, Carbon dioxide) Market - Trends & Forecast to 2020 4Burnham Securities Inc. and The Channel Group Form Healthcare Alliance 2Burnham Securities Inc. and The Channel Group Form Healthcare Alliance 3Atox Bio Awarded Contract Worth up to $24 Million for the Development of AB103 by the Biomedical Advanced Research and Development Authority (BARDA) 2Westbridge Receives EPA Approval for Its New SUPPRESS™ Herbicide EC 2
... Calif., Sept. 29, 2011 Ambry Genetics today ... provide CLIA-approved exome services for applications in clinical ... geneticists and medical directors, these results will allow ... have eluded traditional diagnostic approaches. ...
... 29, 2011 Dr. Barrett Bready, CEO of NABsys, ... Year. Dr. Bready will be honored at a ceremony ... presented by the Providence Business News in partnership with ... Bryant University, Cox Business, Edwards Angell Palmer & Dodge, ...
... system, you probably think about it fighting off a cold. ... immune cells in your brain may contribute to how you ... 10,000 years of using alcohol, and several decades of investigation ... our brain, we are still trying to figure out exactly ...
Cached Biology Technology:Ambry Genetics First to Offer Exome Sequencing Service for Clinical Diagnostics. 2NABsys CEO Barrett Bready Named Rhode Island Innovator of the Year 2Alcohol-related behavior changes -- blame your immune system 2
(Date:9/29/2014)... from the skeleton of a man who lived 2,330 years ... ourselves as humans? A great deal when his DNA profile ... terms found to-date in a region where modern humans ... , The man,s maternal DNA, or ,mitochondrial DNA, was sequenced ... Mitochondrial DNA provided the first evidence that we all come ...
(Date:9/29/2014)... -- NXT-ID, Inc. (Nasdaq: NXTD and ... focused on the growing mobile commerce market, today announced ... the Company,s Vice-President and Chief Financial Officer effective immediately. ... Financial Officer. Mr. Pereira will continue to serve as ... Mr. Miceli, age 56, has extensive hands ...
(Date:9/29/2014)... were able to safely tolerate treatment with cells cultured ... today in the journal Multiple Sclerosis and Related ... its kind, was conducted by researchers at Mount Sinai, ... at several other institutions. , While designed to ... data also suggested that a preparation of cultured cells ...
Breaking Biology News(10 mins):Ancient human genome from southern Africa throws light on our origins 2Ancient human genome from southern Africa throws light on our origins 3NXT-ID, Inc. Names Vice-President and Chief Financial Officer 2NXT-ID, Inc. Names Vice-President and Chief Financial Officer 3Cells from placentas safe for patients with multiple sclerosis 2
... A team led by the University of Colorado Boulder has been ... Energy to research modifying E. coli to produce biofuels ... take what we have worked on for the past decade to ... CU-Boulder,s Renewable and Sustainable Energy Institute, or RASEI. "In this project, ...
... Ian Bell, PhD, the Louis Block Distinguished Service Professor ... the Kovler Diabetes Center at the University of Chicago, ... 2012 for his pioneering work in understanding the role ... The prize, the world,s largest award for ...
... scientists produce better climate-resistant corn and other food production plants ... what we eat. Kansas State University geneticists and colleagues ... and prioritize the genes in humans, it improved the likelihood ... control quantitate traits in plants, such as how the plants ...
Cached Biology News:CU-led team receives $9.2 million DOE grant to engineer E. coli into biofuels 2University of Chicago's Graeme Bell receives international diabetes prize 2University of Chicago's Graeme Bell receives international diabetes prize 3Study finds prioritizing rather than canvassing entire plant genome may lead to improved crops 2Study finds prioritizing rather than canvassing entire plant genome may lead to improved crops 3
High affinity antibody reacting with S-100 ab heterodimer. Could be used for Western blotting application and immunoassay....
... Ingredients (g/L):,Tryptone, 10 ,Yeast extract, ... ,S-Gal, 0.3 ,Ferric ammonium citrate, 0.5 ... patented, water soluble, autoclavable chromogenic substrate ... S-Gal by -galactosidase generates a black ...
S-100 alpha/beta chain (8B10)...
SCCRO (S-17)...
Biology Products: